A single-center, randomized, single-blind, phase 4 study to evaluate the enhancement of mucosal immunity in infants through maternal vaccination during breastfeeding (MEALAC-01).
M-M-RvaxPro powder and solvent for suspension for injection Measlesmumps and rubella vaccine (live)
Eligibility
Age group
0-17 years, 18-64 years
Sex
Female, Male
Primary endpoint
The level of binding antibodies against measles in breastmilk in vaccinated vs unvaccinated mothers, 5 times over 3 months.
Endpoint detail
Phenotype and activation of immune cells in breastmilk
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.